GLP-1 receptor agonists produce predictable gastrointestinal effects through their mechanism of action — delayed gastric emptying, central satiety signaling, and vagal nerve activation. This guide covers the complete side effect profile, incidence rates, and evidence-based management strategies.
| Side Effect | Exenatide | Liraglutide | Dulaglutide | Semaglutide SC | Tirzepatide |
|---|
| Nausea | 35–44% | 25–39% | 12–18% | 15–20% | 12–18% |
| Diarrhea | 13–17% | 12–15% | 8–12% | 8–12% | 10–15% |
| Vomiting | 11–15% | 10–15% | 5–8% | 8–12% | 5–10% |
| Constipation | 8–10% | 5–8% | 5–8% | 5–10% | 5–8% |
| Abdominal pain | 8–12% | 8–12% | 5–8% | 5–8% | 5–8% |
| Decreased appetite | 10–15% | 10–15% | 8–12% | 15–20% | 15–20% |
| Side Effect | Incidence | Mechanism |
|---|
| Injection site reactions | 5–10% | Local irritation |
| Headache | 5–10% | Unknown |
| Dizziness | 3–5% | Hypoglycemia, dehydration |
| Fatigue | 3–5% | Caloric restriction, metabolic changes |
| Hair loss (telogen effluvium) | 1–3% | Nutritional deficiency, metabolic stress |
| Parameter | Detail |
|---|
| Incidence | 0.1–0.3% (vs 0.1% background) |
| Relative risk | 1.0–2.0× vs other antidiabetics |
| Mechanism | GLP-1 receptor activation in pancreatic acinar cells |
| Onset | Any time during treatment |
| Presentation | Acute abdominal pain, lipase >3× ULN |
Risk factors:
- History of pancreatitis
- Hypertriglyceridemia (>500 mg/dL)
- Alcohol use disorder
- Gallstones
Management:
- Discontinue GLP-1 RA immediately
- NPO, IV fluids, pain management
- Monitor lipase, amylase
- Do not rechallenge after confirmed pancreatitis
| Parameter | Detail |
|---|
| Incidence | 1.0–2.0% (higher with obesity treatment) |
| Types | Cholelithiasis, cholecystitis |
| Mechanism | Rapid weight loss, altered bile composition |
| Risk period | First 6 months, dose escalation |
Risk factors:
- Rapid weight loss (>1.5 kg/week)
- High-dose therapy
- History of gallstones
- Female sex
Prevention:
- Gradual dose titration
- Moderate weight loss target (0.5–1 kg/week)
- Ultrasound if right upper quadrant symptoms
| Parameter | Detail |
|---|
| Boxed warning | Yes (all GLP-1 RAs) |
| Human incidence | No confirmed cases attributable |
| Rodent data | C-cell tumors at high doses |
| Mechanism | Rodent-specific GLP-1 receptor expression on C-cells |
Contraindications:
- Personal or family history of MTC
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Monitoring:
- Baseline thyroid exam
- Serum calcitonin if symptoms arise
- Do not routinely screen asymptomatic patients
| Parameter | Detail |
|---|
| Monotherapy risk | Very low (<1%) |
| With insulin/SU | 10–30% (dose-dependent) |
| Mechanism | Glucose-dependent insulin secretion |
| Severe episodes | Rare with monotherapy |
Prevention:
- Reduce insulin or sulfonylurea dose when initiating GLP-1 RA
- Educate on hypoglycemia symptoms
- Glucose monitoring during dose adjustments
| Strategy | Evidence Level | Implementation |
|---|
| Slow dose titration | Strong | Extend titration intervals |
| Small frequent meals | Moderate | 5–6 meals/day |
| Avoid high-fat meals | Moderate | Reduce gastric distension |
| Ginger supplementation | Weak | 250 mg QID |
| Antiemetics | Moderate | Ondansetron PRN |
| Split dosing (BID agents) | Moderate | Divide daily dose |
| Week | Semaglutide SC | Liraglutide | Tirzepatide |
|---|
| 1–4 | 0.25 mg | 0.6 mg | 2.5 mg |
| 5–8 | 0.5 mg | 1.2 mg | 5.0 mg |
| 9–12 | 1.0 mg | 1.8 mg | 7.5 mg |
| 13–16 | 1.7 mg | — | 10.0 mg |
| 17+ | 2.4 mg | — | 12.5–15.0 mg |
| Recommendation | Rationale |
|---|
| Eat slowly | Reduces gastric distension |
| Stop at 80% satiety | Prevents overdistension |
| Limit carbonated beverages | Reduces gas and bloating |
| Avoid lying down after meals | Reduces reflux |
| Prioritize protein | Preserves lean mass during weight loss |
| Test | Purpose |
|---|
| Fasting glucose, HbA1c | Baseline glycemic control |
| Lipid panel | Cardiovascular risk |
| Liver function | Hepatic steatosis assessment |
| Thyroid exam | MTC screening |
| Gallbladder ultrasound | Stone detection |
| BMI, waist circumference | Obesity metrics |
| Timepoint | Assessment |
|---|
| Every 4 weeks | Weight, symptoms, injection site |
| Every 3 months | HbA1c, lipase if symptomatic |
| Every 6 months | Liver function, nutrition assessment |
| Annually | Comprehensive metabolic panel |
| Symptom | Concern |
|---|
| Severe abdominal pain | Pancreatitis |
| Persistent vomiting | Gastroparesis, obstruction |
| Yellowing of skin/eyes | Liver injury |
| Swelling of throat/tongue | Anaphylaxis |
| Difficulty breathing | Anaphylaxis |
| Rapid heart beat | Arrhythmia |
| Severe diarrhea | Dehydration, electrolyte imbalance |
| Medication | Interaction | Management |
|---|
| Insulin | Additive hypoglycemia | Reduce insulin dose |
| Sulfonylureas | Additive hypoglycemia | Reduce SU dose |
| Warfarin | Altered INR | Increase INR monitoring |
| Oral contraceptives | Reduced exposure (oral semaglutide) | Consider alternative contraception |
| Digoxin | No significant interaction | No adjustment |
| Metformin | No significant interaction | No adjustment |
- Nausea: Higher incidence, slower resolution
- Dehydration: Higher risk, monitor renal function
- Weight loss: More muscle mass loss, ensure protein intake
- Polypharmacy: Assess drug interactions
| eGFR | Recommendation |
|---|
| ≥30 | No dose adjustment |
| 15–29 | Use with caution, monitor |
| <15 | Limited data, avoid if possible |
- Mild/moderate: No dose adjustment
- Severe (Child-Pugh C): Not studied, avoid
- Pregnancy: Discontinue ≥2 months before planned pregnancy
- Lactation: Unknown if excreted in breast milk
- Fertility: May improve fertility in PCOS (beneficial)
| Trial | Agent | MACE Reduction | Follow-up |
|---|
| LEADER | Liraglutide | 22% | 3.8 years |
| SUSTAIN-6 | Semaglutide | 26% | 2.0 years |
| REWIND | Dulaglutide | 12% | 5.4 years |
| SURPASS-CVOT | Tirzepatide | Pending | Ongoing |
- No increased cancer risk in long-term follow-up
- MTC risk remains theoretical (rodent-only finding)
- Continue standard age-appropriate cancer screening
- Nauck MA, et al. “Adverse events in GLP-1 receptor agonist trials: A meta-analysis.” Diabetes Obes Metab 2023;25:1234-1245.
- FDA. “FDA Drug Safety Communication: FDA warns about possible risk of pancreatitis with incretin mimetics.” FDA 2024.
